|
413 Companies |
|
276 Products |
|
276 Products |
|
144 Mechanisms of Action |
|
557 Trials |
|
45749 News |
|
| «12...1516171819202122232425...645646» |
- Rytelo (imetelstat) / Geron
IMproveMF update: Phase 1/1B trial of imetelstat (IME)+ruxolitinib (RUX) in patients (pts) with intermediate (INT)-1, INT-2, or high-risk (HR) myelofibrosis (MF). (E450a) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2885;
P1, P2
AEs were consistent with those observed in other IME clinical trials, and preliminary efficacy was positive, demonstrating the potential of IME+RUX in this pt population with high unmet needs. Part 2 of this trial is ongoing across the US at 6 sites.
- Scemblix (asciminib) / Novartis
Efficacy and safety of asciminib (ASC) in patients (pts) with chronic-phase chronic myeloid leukemia (CML-CP) after 1 tyrosine kinase inhibitor (TKI): Interim analysis (IA) of the phase 2 ASC2ESCALATE trial. (E450a) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2882;
P2
ASC was tolerable with few AEs leading to discontinuation. These IA results support ASC as a Tx option in 2L CML-CP.
- lisaftoclax (APG-2575) / Ascentage Pharma
Phase 1b/2 study of lisaftoclax (APG-2575) combined with azacitidine (AZA) in patients (pts) with treatment-na (S100a) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2876;
P1/2
No DLTs occurred. The MTD was not reached.
- Venclexta (venetoclax) / Roche, AbbVie
Phase II study of cladribine, low-dose cytarabine, and venetoclax, alternating with azacitidine and venetoclax, in higher-risk chronic myelomonocytic leukemia and myelodysplastic syndromes. (S100a) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2875;
P2
The MTD was not reached. CDA, LDAC and VEN is safe in pts with HR-MDS and CMML, demonstrating promising results in ND pts.
- ziftomenib (KO-539) / Kura Oncology, Kyowa Kirin
Ziftomenib in relapsed/refractory (R/R) NPM1-mutant acute myeloid leukemia (AML): Phase 1b/2 clinical activity and safety results from the pivotal KOMET-001 study. (S100a) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2874;
P1/2
CDA, LDAC and VEN is safe in pts with HR-MDS and CMML, demonstrating promising results in ND pts. Median age was 69 yrs (range 22
- Inqovi (decitabine/cedazuridine) / Otsuka
An all-oral regimen of decitabine-cedazuridine (DEC-C) plus venetoclax (VEN) in patients (pts) with newly diagnosed acute myeloid leukemia (AML) ineligible for intensive induction chemotherapy: Results from a phase 2 cohort of 101 pts. (S100a) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2871;
P1/2
The all-oral regimen of DEC-C plus VEN resulted in comparable safety, response, and survival rates to parenteral AZA plus VEN in pts with newly diagnosed AML ineligible for intensive induction chemotherapy. These data support the potential use of DEC-C plus VEN as a treatment option for these pts.
- ICT01 / ImCheck Therap
?9?2 T-cell activation (??TCA) with ICT01 combined with azacitidine-venetoclax (AV) for older/unfit adults with newly diagnosed (ND) AML: Preliminary efficacy and dose selection in phase 1/2 study EVICTION. (S100a) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2870;
P1/2
Both ICT01 regimens were safe and very well tolerated and generated very high CR and CR/CRi rates in older/unfit ND-AML pts. The high response rates seen in adverse risk pts warrant further clinical investigation.
- Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz
V-RULES: Real-world effectiveness and safety of CPX-351 in patients with secondary acute myeloid leukemia (AML). (Hall A - Posters and Exhibits; Poster Bd #: 136) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2859;
Notably, this study demonstrated favorable outcomes for younger patients (<60 years) who were not included in the pivotal trial. Patients who received HCT also had improved outcomes, as did those with MRm.
- Duoenda (mitoxantrone liposomal) / CSPC Pharma
Mitoxantrone hydrochloride liposome combined with cytarabine (MA) for patients with newly diagnosed secondary acute myeloid leukemia. (Hall A - Posters and Exhibits; Poster Bd #: 149) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2857;
P=N/A
Patients who received HCT also had improved outcomes, as did those with MRm. The MA regimen demonstrated encouraging remission rates and a superior safety profile, indicating its potential as a treatment option for newly diagnosed sAML.
- Venclexta (venetoclax) / Roche, AbbVie
Venetoclax as cytoreductive therapy in high-risk acute promyelocytic leukemia: A potential alternative to anthracyclines. (Hall A - Posters and Exhibits; Poster Bd #: 137) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2854;
Venetoclax effectively reduced tumor burden while minimizing the risks associated with anthracyclines. These encouraging results warrant further investigation into the potential role of venetoclax in high-risk APL to improve patient outcomes and mitigate treatment-related toxicities.
- Monjuvi (tafasitamab-cxix) / Incyte, Rituxan (rituximab) / Roche
Initial results from a phase II study of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH) (Hall A - Posters and Exhibits; Poster Bd #: 156) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2851;
P2
The addition of blinatumomab to frontline chemotherapy improves survival, but regimens used are limited by toxicity and complexity. In a cohort of ND Ph- B-ALL, the addition of tafa to DA-EPOCH
- Venclexta (venetoclax) / Roche, AbbVie, Inqovi (decitabine/cedazuridine) / Otsuka
Phase II trial of 10-day ASTX727 (decitabine/cedazuridine) in combination with venetoclax for relapsed or refractory acute myeloid leukemia. (Hall A - Posters and Exhibits; Poster Bd #: 167) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2844;
P2
The 10-day ASTX727-VEN combination showed safety profile comparable to other HMA-VEN regimens in salvage setting. TP53 wild type, VEN-na
- Rytelo (imetelstat) / Geron
IMpactMF, randomized, open-label, phase 3 trial of imetelstat (IME) versus best available therapy (BAT) in patients (pts) with intermediate-2 (INT-2) or high-risk (HR) myelofibrosis (MF) relapsed or refractory (R/R) to Janus kinase inhibitors (JAKi). (Hall A - Posters and Exhibits; Poster Bd #: 200a) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2840;
P2, P3
TP53 wild type, VEN-na Randomization is to IME sodium 9.4 mg/kg (8.9 mg/kg active dose) intravenously q3w or investigator-selected BAT (eg, hypomethylating agents, hydroxyurea, interferon, thalidomide, danazol, chemotherapy, or other non
- Besremi (ropeginterferon alfa-2b-njft) / PharmaEssentia
Ropeginterferon alfa-2b for pre-fibrotic primary myelofibrosis and DIPSS low/intermediate-risk myelofibrosis. (Hall A - Posters and Exhibits; Poster Bd #: 189) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2831;
P2
Randomization is to IME sodium 9.4 mg/kg (8.9 mg/kg active dose) intravenously q3w or investigator-selected BAT (eg, hypomethylating agents, hydroxyurea, interferon, thalidomide, danazol, chemotherapy, or other non Ropeg-IFN-?2b was well-tolerated and induced clinical, hematologic and molecular responses in patients with pre-PMF and low/intermediate-1-risk MF.
- Venclexta (venetoclax) / Roche, AbbVie, Noxafil (posaconazole) / Merck (MSD)
Comparable efficacy of venetoclax 50mg with posaconazole versus venetoclax 400mg in newly diagnosed AML patients: A prospective study of pharmacokinetics, toxicity, and clinical outcomes. (Hall A - Posters and Exhibits; Poster Bd #: 146) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2806;
Our findings suggest that lower plasma levels achieved with VEN50 can lead to comparable CR rate & MRD negative rate in comparison with VEN400 with lesser myelotoxicity. Comparison of baseline characteristics and outcomes.
- BAT8006 - Bio / Thera Solutions
Safety and efficacy of BAT8006, a folate receptor ? (FR?) antibody drug conjugate, in patients with platinum-resistant ovarian cancer: Update on the dose optimization/expansion cohort of BAT-8006-001-CR trial. (S100bc) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2796;
P1
expression ?1%. On the basis of these findings, the target population, dose and schedule have been identified for a phase III trial of BAT8006 monotherapy in PROC patients.
- INCB123667 / Incyte
Safety and preliminary efficacy from a phase 1 study of INCB123667, a selective CDK2 inhibitor, in patients with advanced platinum-resistant and refractory ovarian cancer (OC). (S100bc) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2792;
P1
In this phase 1 study of pts with heavily pretreated advanced/metastatic platinum-r/r OC, single agent INCB123667 at various doses showed an acceptable safety profile including expected cytopenia and nausea. The encouraging antitumor activity in this difficult-to-treat population support the advancement of INCB123667 into pivotal studies in pts with platinum-resistant OC.
- TheraCIM (nimotuzumab) / Daiichi Sankyo, Oncoscience, Biocon
Nimotuzumab combined with chemotherapy in the first-line treatment for patients with stage IVB, recurrent or persistent cervical squamous cell carcinoma: A multi-center, randomized, double-blind, and controlled study. (S100bc) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2791;
The encouraging antitumor activity in this difficult-to-treat population support the advancement of INCB123667 into pivotal studies in pts with platinum-resistant OC. Adding nimotuzumab to chemotherapy in the first-line treatment for stage IVB, recurrent or persistent cervical squamous cell carcinoma could have an improvement trend on progression-free and overall survival with well tolerated toxicity, and should be considered as a new first-line therapy option.
- Verzenio (abemaciclib) / Eli Lilly
Phase 2 study of letrozole, abemaciclib, and metformin in estrogen receptor (ER) (S100bc) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2790;
P2
Addition of metformin (at plasma concentrations sufficient to inhibit the PI3K pathway) to letrozole/abemaciclib is feasible and safe, and appears to induce deeper responses (including complete responses) and more prolonged PFS than letrozole/abemaciclib alone. NSMP tumors without RB1 and CCNE1 alterations derive the most benefit from this regimen.
- relacorilant (CORT125134) / Corcept Therap
ROSELLA: A phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer (GOG-3073, ENGOT-ov72). (S100a) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2779;
P3
NSMP tumors without RB1 and CCNE1 alterations derive the most benefit from this regimen. Key eligibility criteria included 1
- Keytruda (pembrolizumab) / Merck (MSD), Lynparza (olaparib) / Merck (MSD), AstraZeneca
A phase II trial of pembrolizumab plus olaparib for the treatment of patients with persistent/recurrent endometrial cancers. (Hall A - Posters and Exhibits; Poster Bd #: 495) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2745;
P2
The combination of PEM + OLA has promising activity with durable responses observed in pts with persistent/recurrent TP53-mutant EC, including carcinosarcomas. Molecular subtype selection is critical in further investigation of this combination.
- OvaRex (oregovomab) / CanariaBio
Oregovomab in combination with non-platinum chemotherapy for the treatment of PARP inhibitor (Hall A - Posters and Exhibits; Poster Bd #: 485) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2737;
P2
Molecular subtype selection is critical in further investigation of this combination. Oregovomab plus weekly paclitaxel chemotherapy demonstrated encouraging activity and safety in heavily pre-treated PARPi- and platinum-resistant EOC.
- HB0025 / Zhejiang Huahai Pharma
A phase II efficacy and safety study of HB0025 (a PD-L1/VEGF bispecific antibody) in combination with chemotherapy as first-line treatment for advanced or recurrent endometrial cancer. (Hall A - Posters and Exhibits; Poster Bd #: 500) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2733;
P1/2
Regardless MMR status, ORR with HB0025 plus CP improved significantly over histologically reported data. A multicentre, randomized, double-blind, controlled phase III trial will commence in 2025.
- Partruvix (pamiparib) / BeiGene
Neoadjuvant pamiparib in patients with newly diagnosed advanced ovarian cancer: A single-arm, prospective phase II trial. (Hall A - Posters and Exhibits; Poster Bd #: 491) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2728;
The preliminary results suggest that the addition of pamiparib to neoadjuvant chemotherapy plus bevacizumab offers promising efficacy and acceptable safety in newly diagnosed advanced ovarian cancer. Further data will be provided as the study progresses.
- INCB123667 / Incyte
Interim safety and antitumor activity data from a phase 1 study of INCB123667, a selective CDK2 inhibitor, in patients with metastatic recurrent endometrial cancer. (Hall A - Posters and Exhibits; Poster Bd #: 501) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2707;
P1
In this interim analysis, single-agent INCB123667 at various doses has shown an acceptable safety profile in pretreated pts with metastatic recurrent endometrial cancer, including expected cytopenia. The encouraging antitumor activity including post-PD-1 based therapy failure supports future development of INCB123667 in advanced/metastatic endometrial cancer.
- Sulanda (surufatinib) / Hutchmed, Partruvix (pamiparib) / BeiGene
A prospective, single-arm, phase 2 trial exploring the use of pamiparib combined with surufatinib as neoadjuvant therapy for advanced, unresectable ovarian cancer (PASSION). (Hall A - Posters and Exhibits; Poster Bd #: 487) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2697;
P2
The encouraging antitumor activity including post-PD-1 based therapy failure supports future development of INCB123667 in advanced/metastatic endometrial cancer. Pamiparib and surufatinib show promising efficacy and manageable toxicity in advanced OC, reshaping the tumor microenvironment and promoting immune infiltration.
- Aidixi (disitamab vedotin) / Pfizer
Preliminary analysis of disitamab vedotin combined therapy for HER2-expressing platinum-sensitive recurrent ovarian/peritoneal/fallopian tube cancer (Diversity study): A single-arm, multicenter phase II trial. (Hall A - Posters and Exhibits; Poster Bd #: 462) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2686;
P2
Pamiparib and surufatinib show promising efficacy and manageable toxicity in advanced OC, reshaping the tumor microenvironment and promoting immune infiltration. Disitamab vedotin (DV; RC48) is a novel humanized anti-HER2 antibody-drug conjugate (ADC) with greater specificity than conventional agents like paclitaxel...Patients received DV (2.5 mg/kg) plus carboplatin (AUC 5), with or without bevacizumab (7.5
- Avastin (bevacizumab) / Roche, Jemperli (dostarlimab-gxly) / GSK, Zejula (niraparib) / GSK, J&J
Re-VOLVE: Phase II clinical trial in women with ovarian cancer progressing post-PARP inhibitor with treatment adapted to real-time assessment of evolving genomic resistance. (Hall A - Posters and Exhibits; Poster Bd #: 459) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2682;
P2
This strategy was safe and provided clinical benefit to some pts. Further translational analysis is ongoing.
- Trodelvy (sacituzumab govitecan-hziy) / Gilead
A single-center, open-label, single-arm, phase I study with dose expansion cohort of sacituzumab govitecan in combination with cisplatin for patients with platinum sensitive recurrent ovarian and endometrial cancer. (Hall A - Posters and Exhibits; Poster Bd #: 518b) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2680;
P1/2
The study began enrolling patients October 2024 at our institution and is currently in phase 1 at the starting dose level of sacituzumab govitecan. Clinical trial information: NCT06040970.
- albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg.
PANOVA-3: Phase 3 study of tumor treating fields (TTFields) with gemcitabine and nab-paclitaxel for locally advanced pancreatic ductal adenocarcinoma (LA-PAC). (Hall D1) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2657;
P3
PANOVA-3 is the largest phase 3 trial exclusively performed in patients with LA-PAC and the first to show a statistically significant OS benefit. With no additive systemic toxicity and a statistically significant pain-free survival benefit, TTFields therapy is a potential new standard treatment for LA-PAC.
- 5-fluorouracil / Generic mfg., irinotecan / Generic mfg.
Results of a randomized phase III trial of pre-operative chemotherapy with mFOLFIRINOX or PAXG regimen for stage I-III pancreatic ductal adenocarcinoma. (Hall D1) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2656;
P3
CASSANDRA (NCT04793932) is a multicenter phase 3 superiority trial randomizing pts ?75y with R/BR PDAC, stratified by site and CA19.9, in a 2 by 2 factorial design to receive either PAXG (oral daily capecitabine 1250 mg/m2 with biweekly cisplatin 30 mg/m2, nab-paclitaxel 150 mg/m2, gemcitabine 800 mg/m2; arm A) or mFOLFIRINOX (biweekly 5-fluorouracil 2400 mg/m2, irinotecan 150 mg/m2, oxaliplatin 85 mg/m2; arm B; 1st random) for either 6 months before or 4 months before and 2 months after surgery (2nd random). Neoadjuvant PAXG significantly improved EFS compared to mFOLFIRINOX in pts with R/BR PDAC.
- elraglusib (9-ING-41) / Actuate Therap
Preliminary results from the randomized phase 2 study (1801 part 3B) of elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) versus GnP alone in patients (pts) with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC). (Hall D1) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2651;
P2
The mOS for GnP is lower relative to MPACT and NAPOLI-3 but comparable to recent real-world meta-analyses, explained by advanced disease burden and higher mortality rate in the first 4 months in our study. Topline analysis (April 2025) and correlative biomarker analysis predictive for OS will be presented.
- Aqupla (nedaplatin) / Simcere, Fruzaqla (fruquintinib) / Takeda, AiRuiKa (camrelizumab) / HLB Bio Group
Fruquintinib in combination with camrelizumab and paclitaxel liposome and nedaplatin as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, phase II study. (Hall A - Posters and Exhibits; Poster Bd #: 332) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2643;
P1/2
Topline analysis (April 2025) and correlative biomarker analysis predictive for OS will be presented. The combination of fruquintinib, camrelizumab, paclitaxel liposome, and nedaplatin demonstrated significant efficacy and manageable toxicity profile as a first-line treatment for advanced ESCC, suggesting a potential new treatment strategy.
- Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, Herzuma (trastuzumab-pkrb) / Nippon Kayaku, Mundipharma, Celltrion, Teva
A multicenter randomized phase II study of trastuzumab biosimilar (CT-P6) and chemotherapy (SOX or CapeOX) in HER2-positive advanced/recurrent gastric cancer (KSCC: TROX study). (Hall A - Posters and Exhibits; Poster Bd #: 319) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2633;
Clinical Trial Registration Number: jRCTs071190007 Background: The efficacy and safety of the trastuzumab biosimilar (CT-P6) combined with S-1/oxaliplatin (SOX) or capecitabine/oxaliplatin (CapeOX) were investigated in patients with HER2-positive advanced or recurrent gastric cancer who had not previously received chemotherapy... Trastuzumab biosimilar (CT-P6) combined with SOX or CapeOX demonstrated robust antitumor efficacy and manageable toxicity in patients with advanced or recurrent gastric cancer.
- Lonsurf (trifluridine/tipiracil) / Otsuka
First results of an open-label, single arm phase II trial investigating the efficacy and safety of trifluridine/tipiracil combined with irinotecan as a second line therapy in patients with cholangiocarcinoma. (Hall A - Posters and Exhibits; Poster Bd #: 411) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2598;
P2
Further investigations are warranted to validate these results. The NIFTY trial suggested that pegylated irinotecan may enhance efficacy compared to conventional irinotecan, a hypothesis that will be explored in the planned follow-up TRITICC-2 study.
- Hetronifly (serplulimab) / Fosun Pharma
Phase II trial of serplulimab combined with gemcitabine plus nab-paclitaxel (GnP) and SBRT for metastatic pancreatic cancer as the first-line treatment. (Hall A - Posters and Exhibits; Poster Bd #: 450) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2591;
P2
This phase II study has met our preset primary endpoint with 78.48% in 6-month PFS rate, and SGSBRT presented promising efficacy with manageable safety profile and expected antitumor activity. This combination might be a promising option as first-line therapy for Chinese patients with mPDAC.
- Phase II trial of transarterial chemoembolization followed by sintilimab (anti-PD-1), oxaliplatin, and S-1 combined with either trastuzumab (HER-2 positive) or apatinib (HER-2 negative) as first-line therapy for gastric cancer with liver metastases. (Hall A - Posters and Exhibits; Poster Bd #: 340) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2549;
P2
TACE followed by sintilimab, oxaliplatin and S-1 combined with either trastuzumab or apatinib demonstrated promising efficacy and manageable safety as first-line therapy for GCLM. Gastric cancer and its paired liver metastases exhibited distinct gene mutations and immune microenvironment.
- misetionamide (GP-2250) / Panavance Therap
Interim open-label phase 1 results of misetionamide (GP-2250): A small molecule antineoplastic targeting three major transcription factors. (Hall A - Posters and Exhibits; Poster Bd #: 467) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2538;
P1
These promising results in a historically difficult to treat pancreatic cancer population warrant progress to later-stage studies. This study is funded by Geistlich Pharma AG.
- pevonedistat (MLN4924) / Takeda
A phase II study of pevonedistat in combination with carboplatin and paclitaxel in advanced intrahepatic cholangiocarcinoma: ECOG-ACRIN EA2187. (Hall A - Posters and Exhibits; Poster Bd #: 405) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2537;
P2
These findings highlight the challenges in treating this aggressive malignancy. Despite the rarity of ICC, the rapid accrual of this study during a global pandemic indicates the potential for continued exploration of novel therapeutic approaches in this disease.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Real-world predictors of adverse clinical outcomes in pancreatic cancer using a machine-learning framework. (Hall A - Posters and Exhibits; Poster Bd #: 476) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2532;
Early prognostic indicators of adverse outcomes can guide early management for high-risk individuals through supportive measures and dose modification, before high-grade toxicities and discontinuations wherein patients can no longer benefit from therapy. Summary of FOLFIRINOX Model Outputs Across Clinical Outcomes.
- cisplatin / Generic mfg., paclitaxel / Generic mfg.
The lost evidence: A phase III, multicenter randomized controlled trial of neoadjuvant chemotherapy paclitaxel plus cisplatin versus surgery alone for stage IIA (Hall A - Posters and Exhibits; Poster Bd #: 364) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2528;
P3
Summary of FOLFIRINOX Model Outputs Across Clinical Outcomes. This trial showed that NAC plus surgery improves survival over surgery alone among patients with locally advanced ESCC, with acceptable and manageable adverse events.
- Sulanda (surufatinib) / Hutchmed
Efficacy and safety of surufatinib (Sur) plus paclitaxel (Pac) as second line (2L) treatment for advanced gastric cancer (aGC): Final results from a phase 2 trial. (Hall A - Posters and Exhibits; Poster Bd #: 318) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2526;
P=N/A
Although ramucirumab plus Pac have been approved as a 2L treatment, access to this combination regimen is limited in China. These encouraging long-term efficacy results and the manageable safety profile suggested a preferable position of Sur plus Pac as the 2L treatment for aGC, notably, following the current standard 1L IO-containing regimens.
- Sulanda (surufatinib) / Hutchmed, IMC001 / Immunofoco, erfonrilimab (KN046) / Alphamab
Efficacy and safety of surufatinib (S) plus KN046 (K) and chemotherapy in first line (1L) advanced pancreatic cancer (PC): A single-arm, phase 1b/2 trial. (Hall A - Posters and Exhibits; Poster Bd #: 447) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2523;
P1/2
Funded by HUTCHMED, ALPHAMAB Clinical Trial Registration Number: NCT05832892 Background: Gemcitabine (G) and nab-paclitaxel (nP) are standard 1L regimen for patients (pts) with unresectable PC, yet the efficacy remains unsatisfactory... These preliminary results showed encouraging anti-tumor efficacy and an acceptable safety profile of S plus K and GnP chemotherapy as 1L treatment for advanced PC.
- Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, Hetronifly (serplulimab) / Fosun Pharma, Herceptin (trastuzumab) / Roche
Safety, efficacy, and biomarker analysis from a phase II trial of intensive chemotherapy combined with serplulimab and trastuzumab in patients with advanced HER2-positive gastric cancer. (Hall A - Posters and Exhibits; Poster Bd #: 321) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2519;
P2
These preliminary results showed encouraging anti-tumor efficacy and an acceptable safety profile of S plus K and GnP chemotherapy as 1L treatment for advanced PC. Pts receive Serplulimab (4.5 mg/kg, D1, Q3W), Trastuzumab (initial 8 mg/kg, D1, then 6 mg/kg, D1, Q3W), and the DOS regimen: oxaliplatin (100 mg/m
- Focus V (anlotinib) / Advenchen, Sino Biopharm, TQB2868 / Sino Biopharm
TQB2868 combined with anlotinib and nab-paclitaxel plus gemcitabine as first-line treatment for metastatic pancreatic cancer: A prospective, multicenter, single-arm, phase 2 study. (Hall A - Posters and Exhibits; Poster Bd #: 449) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2514;
P2
Pts receive Serplulimab (4.5 mg/kg, D1, Q3W), Trastuzumab (initial 8 mg/kg, D1, then 6 mg/kg, D1, Q3W), and the DOS regimen: oxaliplatin (100 mg/m TQB2868 combination regimen as first-line treatment was demonstrated to be tolerable, with promising anti-tumor activity in mPDAC.
- utidelone IV (UTD1) / Beijing Biostar Technologies
Efficacy and safety results of a multi-center phase II study of utidelone injection in combination with PD-1 inhibitor and chemotherapy for the first-line treatment of advanced gastric and esophagus cancers. (Hall A - Posters and Exhibits; Poster Bd #: 330) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2503;
P2
TQB2868 combination regimen as first-line treatment was demonstrated to be tolerable, with promising anti-tumor activity in mPDAC. Eligible patients were recruited into the two cohorts of metastatic and/or unresectable HER2 negative GC or ESCC, receiving utidelone (30mg/m2/day iv on days 1
- Imfinzi (durvalumab) / AstraZeneca
Neo-adjuvant chemo-immunotherapy in pancreatic cancer: Results of the Australasian Gastrointestinal Trials Group (AGITG) NEO-IMPACT pilot trial. (Hall A - Posters and Exhibits; Poster Bd #: 479) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2498;
P2
Neoadjuvant chemoimmunotherapy is feasible and safe for patients with resectable and borderline resectable pancreas cancer. A 10% CPR rate and 70% R0 resection rate are encouraging, and this approach should be further explored in a larger population.
- Tevimbra (tislelizumab-jsgr) / BeiGene, Aidixi (disitamab vedotin) / Pfizer
Disitamab vedotin (RC48), tislelizumab, and S-1 as first-line therapy for HER2-overexpressing advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Updated results from the RCTS trial. (Hall A - Posters and Exhibits; Poster Bd #: 349) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2494;
P2
The combination of RC48, tislelizumab and S-1 as a first-line therapy shows encouraging response rates and survival benefits in HER2-overexpressing GC/GEJC, especially in HER2-positive or CPS ?1 patients, supporting further evaluation in randomized controlled trials. Clinical trial: NCT05586061.
- IMC001 / Immunofoco, EBC-129 / A*Star, National Cancer Centre Singapore
Clinical activity of EBC-129, a first-in class, anti N256-glycosylated CEACAM5 and CEACAM6 antibody-drug conjugate (ADC), in patients with pancreatic ductal adenocarcinoma (PDAC) in a phase 1 study. (Hall D2) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2457;
P1
Further evaluation of EBC-129 in PDAC, both as monotherapy and in combination with chemotherapy, is planned. (NCT05701527).
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Clinical implications and prevalence of benign ethnic neutropenia (BEN) in breast cancer patients of Middle Eastern ethnicity. (Hall A - Posters and Exhibits; Poster Bd #: 367) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2326;
Duffy phenotyping can be used in place of more invasive tests to identify these patients. Treatment delays due to apparent neutropenia are common, however, response to filgrastim is universal, and febrile neutropenia episodes are rarely seen.